Patient-Reported Outcomes from Phase 3 Baricitinib Ra-Beam Study: Latin American Subgroup Analysis

Phase 3 ◽

Patient-Reported outcomes from Phase 3 Baricitinib Ra-Begin Study: Latin American Subgroup Analysis

Value in Health ◽

10.1016/j.jval.2017.08.2986 ◽

2017 ◽

Vol 20 (9) ◽

pp. A939

Author(s):

M Papadimitropoulos ◽

C Zerbini ◽

C Ramos-Remus ◽

P Martinez-Osuna ◽

B Zhu ◽

...

Keyword(s):

Latin American ◽

Subgroup Analysis ◽

Phase 3 ◽

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.95 ◽

2017 ◽

Vol 1 ◽

pp. s96

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Abstract Not AvailableDisclosure: Study supported by Dermira.

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.supp.41 ◽

2018 ◽

Vol 2 ◽

pp. S41

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Abstract not available. Disclosures: Study supported by Dermira. Copyright SKIN 2018

Effectiveness of Dimethyl Fumarate on Disease Activity and Patient-Reported Outcomes in French Subjects with Relapsing-Remitting Multiple Sclerosis in the Real-World: A Subgroup Analysis of PROTEC

10.26226/morressier.59a3edabd462b8028d8950aa ◽

2017 ◽

Author(s):

Zeynep ['Brochet']

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Real World ◽

Subgroup Analysis ◽

Relapsing Remitting Multiple Sclerosis

Dimethyl Fumarate ◽

The Real ◽

Patient Reported ◽

Relapsing Remitting ◽

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy: Table 1.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.1239 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 412.2-413 ◽

Cited By ~ 1

Author(s):

E. Keystone ◽

P. Taylor ◽

Y. Tanaka ◽

C. Gaich ◽

A.M. DeLozier ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Inadequate Response ◽

Phase 3 ◽

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-019-02894-3 ◽

2019 ◽

Vol 145 (6) ◽

pp. 1589-1599 ◽

Cited By ~ 6

Author(s):

Jorge E. Cortes ◽

◽

Carlo Gambacorti-Passerini ◽

Michael W. Deininger ◽

Michael J. Mauro ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Chronic Phase ◽

Newly Diagnosed ◽

Phase 3 ◽

Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17109 ◽

2021 ◽

Author(s):

D Thaçi ◽

AM Soliman ◽

K Eyerich ◽

A Pinter ◽

M Sebastian ◽

...

Keyword(s):

Clinical Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Patient Reported ◽

Acid Esters

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00110-2 ◽

2021 ◽

Author(s):

Arndt Vogel ◽

Shukui Qin ◽

Masatoshi Kudo ◽

Yun Su ◽

Stacie Hudgens ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Unresectable Hepatocellular Carcinoma ◽

Carcinoma Patient ◽

Patient Reported ◽

First Line Treatment

LB755 Patient-reported outcomes with sarecycline treatment for Acne Vulgaris: Pooled analysis of phase 3 clinical studies

Journal of Investigative Dermatology ◽

10.1016/j.jid.2021.07.097 ◽

2021 ◽

Vol 141 (9) ◽

pp. B12

Author(s):

J. Harper ◽

A. Armstrong ◽

R. Fried ◽

E. Rieder ◽

A. Alvarez-Dieppa ◽

...

Keyword(s):

Clinical Studies ◽

Acne Vulgaris ◽

Pooled Analysis ◽

Phase 3 ◽

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

British Journal of Cancer ◽

10.1038/sj.bjc.6604053 ◽

2007 ◽

Vol 97 (11) ◽

pp. 1469-1474 ◽

Cited By ~ 57

Author(s):

S Siena ◽

M Peeters ◽

E Van Cutsem ◽

Y Humblet ◽

P Conte ◽

...

Keyword(s):

Progression Free Survival ◽

Phase 3 ◽

Free Survival ◽